Previous Article | Next Article ![]()
Eukaryotic Cell, April 2009, p. 617-626, Vol. 8, No. 4
1535-9778/09/$08.00+0 doi:10.1128/EC.00366-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
,
Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom,1 Division of Molecular Physiology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom2
Received 12 November 2008/ Accepted 16 January 2009
|
|
|---|
|
|
|---|
30,000 deaths per annum (35). However, despite the lack of conventional tyrosine kinases in this parasite and related trypanosomes, there is evidence that several proteins are phosphorylated on tyrosine residues in these organisms (10, 30). Tyrosine phosphatase activity has also been observed in cell extracts of bloodstream form and procyclic form T. brucei (1). More recently, the identification and biochemical characterization of a T. brucei protein tyrosine phosphatase 1 suggest a role for tyrosine phosphorylation in the regulation of the trypanosome life cycle (36). In addition, the characterization of the T. brucei protein phosphatase complement ("phosphatome") revealed the presence of 19 dual-specificity protein phosphatases. However, orthologues of the human mitogen-activated protein kinase (MAPK) phosphatases are missing in the T. brucei genome (3), although plant-like MAPK phosphatase homologues are present. This is an interesting observation, since our large-scale phosphoproteomics analysis of bloodstream form T. brucei cells (Nett et al., submitted for publication) revealed phosphorylation on tyrosine residues of 13 protein kinases, of which two belong to the MAPK family (GeneDB accession no. Tb927.6.4220 and Tb10.61.0250). Phosphorylation of protein tyrosine residues regulates important cell functions in higher eukaryotes, but the role of this posttranslational modification is largely unknown for T. brucei. Here, we used a phosphotyrosine-specific mass spectrometry (MS)-based approach to identify proteins carrying this modification in the procyclic form of the parasite and reveal that phosphorylation of tyrosine residues within canonical sequence motifs is conserved in T. brucei. However, by using anti-phosphotyrosine-specific antibodies, we show a localization pattern for phosphotyrosine-containing proteins in T. brucei that is substantially different from that in mammalian cells.
|
|
|---|
For the isolation of phosphotyrosine-containing peptides from trypanosomes, 1 liter of cells was grown to a density of 1 x 107 cells/ml at 28°C in a water-jacketed incubator. Cells were treated with 800 µM hydrogen peroxide for 30 min before lysis. Cell lysis and phosphopeptide preparation were performed using the PhosphoScan P-Tyr-100 kit (Cell Signaling) according to the manufacturer's instructions.
Cell lysis for Western blotting. Before lysis, cells were washed three times in ice-cold phosphate-buffered saline (PBS) buffer and then lysed in ice-cold RIPA lysis buffer (10 mM Tris-HCl, pH 7.5; 1 mM sodium-β-glycerophosphate; 1 mM sodium-pyrophosphate; 1 mM sodium fluoride; 5 mM EDTA; 0.5% NP-40; 0.2% sodium-deoxycholate; 0.2% sodium dodecyl sulfate [SDS]; EDTA-free protease inhibitor tablet [Roche]; 100 µM activated sodium-orthovanadate) at a ratio of 1 x 109 cells per 1 ml of lysis buffer. The lysate was sonicated two times for 30 s at 80% power of an ultrasonic processor machine (Jencons) at 4°C and centrifuged at 14,000 rpm for 20 min at 4°C. The supernatant was transferred into a fresh tube, and the protein concentration determined using the Micro BCA protein assay kit (Pierce) according to the manufacturer's instructions. Approximately 10 µg of proteins were mixed with the appropriate volume of 4x Laemmli sample buffer and 10x sample-reducing agent (Invitrogen), heated, and separated on a precast Novex 4 to 12% Bis-Tris SDS-polyacrylamide electrophoresis gel. After electrophoresis, proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane, and the membrane was blocked with 4% bovine serum albumin in Tris-buffered saline (TBS) (150 mM NaCl, 50 mM Tris-HCl, pH 7.2) containing Triton X-100 (0.2%) for 1 h at room temperature. The membrane was incubated with the anti-phosphotyrosine monoclonal antibody 4G10 (1 mg/ml; Upstate) at a dilution of 1:10,000 for 1 h at room temperature, then washed, and incubated with secondary antibody (anti-mouse horseradish peroxidase; Roche) at 1:5,000. Western blots were developed using the ECL plus Western blotting detection reagent (GE Healthcare) according to the manufacturer's instructions and were exposed to Hyperfilm (GE Healthcare).
To examine phosphotyrosine-containing proteins of cytosol and cytoskeletal fractions, aliquots of 3 x 107 procyclic form T. brucei cells were washed in PBS buffer and lysed in either 100 µl ice-cold MME buffer (10 mM MOPS, pH 6.9; 1 mM EGTA; 1 mM MgSO4) containing EDTA-free protease inhibitor tablet (Roche), 0.2% Triton X-100, and a phosphatase inhibitor cocktail of 1 mM sodium-β-glycerophosphate, 1 mM sodium-pyrophosphate, 1 mM sodium fluoride, and 100 µM activated sodium-orthovanadate or in 100 µl RIPA lysis buffer (see above). The MME lysate was incubated on ice for 30 min and centrifuged at 13,000 x g for 2 min at 4°C. The supernatant was transferred into a fresh tube, and the pellet was washed three times with 1 ml MME buffer containing 0.2% Triton X-100 with protease and phosphatase inhibitors, as described previously. The insoluble cytoskeletons were resolubilized in 100 µl RIPA lysis buffer, and 20-µl aliquots (6 x 106 cell equivalents) of the MME soluble fraction and the RIPA-solubilized cytoskeletal fraction were resolved on a 4 to 12% NuPAGE gel (Invitrogen), alongside 20 µl of the whole-cell RIPA-lysate, and transferred to PVDF. Replicate blots were incubated with either alkaline phosphatase buffer (50 mM Tris-HCl, pH 8.5; 5 mM MgCl2) containing 15 units of shrimp alkaline phosphatase at 30°C overnight or with 10 µg of recombinant glutathione S-transferase-SHP-1 in 50 mM Tris-HCl (pH 7.5), 0.1 mM EGTA, 0.03% Brij 35, 0.1% β-mercaptoethanol. The control blot was incubated in glutathione S-transferase-SHP-1 buffer. Blots were rinsed three times with TBS containing 0.2% Triton X-100 (TBS-T), and Western blotting for phosphotyrosine was performed as described previously. Western blots were stripped in 50 mM Tris-HCl (pH 7), 2% SDS, 0.1% β-mercaptoethanol for 30 min at 65°C and then rinsed three times with TBS containing 0.2% Triton X-100. For a loading control, blots were incubated with the anti-tubulin clone DM1A (1 mg/ml; Abcam) at a dilution of 1:10,000 and then with goat anti-mouse horseradish peroxidase (1:10,000) and developed by enhanced chemiluminescence.
Immunolocalization.
Mid-log procyclic trypanosomes (
1 x 107 cells/ml) were settled onto coverslips for 15 min, and in the case of cytoskeleton preparations, settled cells were incubated with MME buffer (see above) on ice for 10 min with three changes of buffer. Isolated flagellar complexes were obtained by incubating the cells with MME buffer containing 1 M NaCl, 0.2% Triton X-100, and protease and phosphatase inhibitors, as described previously, on ice for 15 min with three changes of buffer. Cells were washed in PBS and fixed in either 4% paraformaldehyde (PFA) in PBS or 100% ice-cold methanol. Coverslips were blocked with 2% fish gelatin in TBS/0.2% Triton X-100 for 1 h at room temperature before antibody labeling with approximately 0.25 µg per coverslip of 4G10 antibody (Upstate), fluorescein isothiocyanate-conjugated 4G10 antibody (Upstate), PY-20 antibody (Transduction Laboratories), or PY-100 antibody (Cell Signaling Technologies) or with a 1:30 dilution in 2% fish gelatin in TBS/0.2% Triton X-100 of BBA4 or Rib72 monoclonal antibody tissue culture supernatant (kind gifts of Keith Gull). Rib72 labeling was visualized with anti-mouse immunoglobulin G (IgG) Alexa Fluor 633 (2 µg/ml; Invitrogen) secondary antibody and 4G10 labeling with either anti-mouse IgG Alexa Fluor 633 (2 µg/ml; Invitrogen) or anti-mouse IgG Alexa Fluor 488 (2 µg/ml; Invitrogen). BBA4 labeling was visualized with anti-mouse IgM Alexa Fluor 488 (2 µg/ml; Invitrogen). Cells were counterstained with anti-mouse fluorescein isothiocyanate-conjugated anti-
tubulin (1.5 µg/ml; Sigma) and/or 4'-6-diamidino-2-phenylindole (2 µg/ml; Sigma) before mounting with Vectashield (Vector Laboratories). For staining of the nucleolus, procyclic cells were incubated with a carboxy-terminal tetramethyl rhodamine isothiocyanate (TRITC)-labeled deca-arginine peptide, TRITC-D(R10) (Peptide Specialty Laboratories GmbH), at a 7 µM final concentration for 1 h at 28°C. Cells were washed once in PBS, resuspended in SDM-79 medium and incubated for another 2 h at 28°C. Cells were then harvested, fixed in 4% PFA/PBS, and mounted as described above.
For the dephosphorylation assay, methanol-fixed trypanosomes were incubated with 2 ml alkaline phosphatase buffer (see above) containing 10 units of alkaline shrimp phosphatase in a six-well plate overnight at 37°C. Positive control cells were incubated in 2 ml alkaline phosphatase buffer only, without the addition of alkaline shrimp phosphatase.
For immunofluorescence studies of human HeLa cells, 2 x 105 cells were seeded onto a square coverslip (22 mm by 22 mm) and incubated at 37°C for 24 h. The cells were washed twice with 1 ml of PBS and fixed in 4% PFA/PBS. Antibody incubations and mounting of cells were performed as described for trypanosomes.
Images were collected using a DeltaVision Spectris restoration wide-field deconvolution microscope (Applied Precision LLC) equipped with a CoolSnap HQ cooled charge-coupled-device camera. Optical sections were processed using SoftWoRx software (Applied Precision LLC) and Adobe Photoshop (Adobe).
LC-MS. Liquid chromatography (LC) was performed on a fully automated UltiMate 3000 Nano LC system (Dionex) fitted with a 1- by 5-mm precolumn PepMap C18 (LC Packings, Dionex) and a 75-µm by 15-cm reverse-phase C18 nano-column (LC Packings, Dionex). Samples were loaded in 0.1% formic acid containing 2% acetonitrile (buffer A) and separated using a binary gradient consisting of buffer A and buffer B (90% acetonitrile, 0.08% formic acid). Peptides were eluted with a linear gradient from 5 to 40% buffer B over 130 min. The high-pressure liquid chromatography system was coupled to an LTQ-Orbitrap mass spectrometer (Thermo Electron) equipped with a proxeon nanospray ionization source.
With the LTQ-Orbitrap mass spectrometer, a survey scan was performed over a mass range of m/z 335 to 1,800 in the Orbitrap analyzer (R = 60,000), each triggering five tandem MS (MS/MS) LTQ acquisitions of the five most intense ions. The Orbitrap mass analyzer was internally calibrated on the fly using the lock mass of polydimethylcyclosiloxane at m/z 445.120025.
Raw peak list files obtained from the LTQ-Orbitrap were converted to Mascot generic files using Raw2msm software (gift from Matthias Mann) and were searched against concatenated forward and reverse sequence databases consisting of amino acid sequences from T. brucei strain 927 and translated open reading frames from T. brucei strain 427 using the Mascot search engine (Mascot V2.1; Matrix Science). The search criteria were as follows: up to two missed cleavages were allowed; carbamidomethylation, oxidation, and phosphorylation were set as variable modifications. The precursor ion mass tolerance was set to 10 ppm and 0.8 Da for all MS/MS spectra acquired in the LTQ mass analyzer.
|
|
|---|
![]() View larger version (38K): [in a new window] |
FIG. 1. Detection of T. brucei tyrosine-phosphorylated proteins by immunoblotting. Aliquots of total cell lysates (T) and TX-100-soluble (S) and insoluble (P) fractions from 6 x 106 procyclic form trypanosome equivalents were subjected to SDS-polyacrylamide gel electrophoresis and Western blotting with 4G10 antibody before (Control, lanes 1 to 3) and after alkaline phosphatase (alk. phosphatase, lanes 4 to 6) or SHP-1 phosphotyrosine-specific phosphatase (SHP-1, lanes 7 to 9) treatment of the blot. Following the 4G10 Western blotting, the membranes were stripped and probed with anti-tubulin antibodies as a loading control (lower panels). -pTyr, anti-phosphotyrosine.
|
![]() View larger version (44K): [in a new window] |
FIG. 2. T. brucei cells are sensitive to treatment with hydrogen peroxide. Procyclic trypanosomes were treated with 200 µM, 400 µM, and 800 µM hydrogen peroxide for 10 min, 20 min, and 30 min before cell lysis. An aliquot of 15 µg protein was loaded in each lane. Lane 1, protein lysate of untreated cells. Bands that show a clear response to the hydrogen peroxide treatment are indicated with an asterisk. -pTyr, anti-phosphotyrosine.
|
![]() View larger version (16K): [in a new window] |
FIG. 3. Mass spectrometric analysis of T. brucei phosphotyrosine-containing peptides. Shown is the fragmentation spectrum of the diphosphorylated peptide GVGVNVpTSpYVVTR (p indicates phosphorylated residue) of a putative TbMAPK (GeneDB accession no. Tb927.6.1780) measured on an LTQ-Orbitrap mass spectrometer. Phosphorylation at the threonine and tyrosine residues of the TSY motif could be deduced due to the neutral loss of phosphoric acid starting from the y7 and b7 ions (–P) and the observed mass increment of 243 Da (+P) between the y4 and y5 ions, respectively.
|
|
View this table: [in a new window] |
TABLE 1. Tyrosine-phosphorylated protein kinases of whole-cell procyclic trypanosomesa
|
Other tyrosine-phosphorylated proteins identified in our study are involved in protein synthesis (GeneDB accession no. Tb927.5.3120 translation initiation factor, putative; ribosomal protein S27, putative), energy metabolism (glycosomal phosphoenolpyruvate carboxykinase; ATP-dependent phosphofructokinase), and RNA metabolism (ATP-dependent DEAD/H RNA helicase, putative). Tyrosine-containing peptides were also found for nonclassified proteins (10 "hypothetical proteins") (see Table 2).
|
View this table: [in a new window] |
TABLE 2. Non-protein kinase tyrosine-phosphorylated proteins of whole-cell procyclic trypanosomesa
|
![]() View larger version (66K): [in a new window] |
FIG. 4. Indirect immunofluorescence using anti-phosphotyrosine antibodies. Whole-cell procyclic trypanosomes were fixed in 4% PFA and stained with 4G10 (A), PY-20 (B), and PY-100 (C). (D) A no-primary-antibody control was included and demonstrated that the staining was a consequence of the primary anti-phosphotyrosine antibodies. Tyrosine-phosphorylated proteins (in green) localized to punctate structures in the posterior of the cells (white arrows) and were also found along the length of the flagellum (yellow arrows) and in the nucleus (white arrowheads). (E and F) Control HeLa cells labeled with 4G10 showed concentrated anti-phosphotyrosine staining (in red) at focal adhesion regions. DNA (blue) is visualized by 4'-6-diamidino-2-phenylindole (DAPI) staining. Anti- -tubulin is shown in green. p-Tyr, tyrosine-phosphorylated proteins. White bar corresponds to a length of 5 µm.
|
![]() View larger version (76K): [in a new window] |
FIG. 5. Indirect immunofluorescence analysis of cytoskeletal preparations using anti-phosphotyrosine antibodies. Procyclic form cytoskeletons were fixed in 4% PFA and stained with 4G10 (A), PY-20 (B), and PY-100 (C). (D) A no-primary-antibody control was included and demonstrated that the staining was a consequence of the primary anti-phosphotyrosine antibodies. The staining pattern suggested labeling of the basal bodies in the posterior of the cell and was observed along the length of the flagellum (in green). DNA (blue) is visualized by 4'-6-diamidino-2-phenylindole (DAPI) staining. White bar corresponds to a length of 5 µm.
|
![]() View larger version (38K): [in a new window] |
FIG. 6. Colocalization studies of phosphotyrosine staining using the anti-basal body marker BBA4. Indirect immunofluorescence of procyclic form T. brucei cytoskeletons colabeled with the anti-phosphotyrosine antibody 4G10 (A) and BBA4 (B), a specific marker for the proximal pole of both basal and probasal structures. Images shown in panels A and B are shown merged in panel C. Differential interference contrast (DIC) images of T. brucei flagella were taken (D) and merged with immunofluorescence images labeled with the anti-phosphotyrosine 4G10 antibody (E). White arrows, labeling of the basal body. Colabeling structures that were observed are enlarged and surrounded by a white box. p-Tyr, tyrosine-phosphorylated proteins. White bar corresponds to a length of 5 µm.
|
![]() View larger version (72K): [in a new window] |
FIG. 7. Phosphotyrosine-containing proteins are associated with the flagellum axoneme. Cytoskeleton preparations of procyclic form T. brucei (A) were colabeled with the anti-phosphotyrosine 4G10 antibody (B) and the anti-axonemal Rib72 antibody (C). The overlap of both staining patterns in most of the areas (D) strongly suggested that the anti-phosphotyrosine signal is axonemal. The area of the phosphotyrosine signal that did not colocalize with the Rib72 staining is indicated with arrows (D). White bar corresponds to a length of 5 µm.
|
|
|
|---|
Other protein kinases identified in this study include the cell division cycle 2 (Cdc2)-related protein kinases CRK1 (GeneDB accession no. Tb10.70.7040), CRK2 (GeneDB accession no. Tb927.7.7360), and CRK3 (GeneDB accession no. Tb10.70.2210), all of which were found to be tyrosine phosphorylated in their N terminus (Y16, Y57, and Y34, respectively). All three CRK isoforms have previously been detected phosphorylated on the same residues in our global phosphoproteome study of bloodstream form T. brucei (Nett et al., submitted for publication), suggesting that life cycle stage-specific tyrosine phosphorylation of these residues can be excluded. Interestingly, the phosphorylated tyrosine sites are flanked by an S15 in CRK1, S56 in CRK2, and T33 in CRK3, which could correspond to the conserved human CDK1 T14 and Y15 residues. Phosphorylation of the conserved Y15 of CDK1 by the Wee1 dual-specificity tyrosine kinase inactivates the CDK complex (20), and as a Wee1 kinase is encoded by the T. brucei genome, it is possible that CRKs in T. brucei are regulated by a similar mechanism.
Our detection of previously identified trypanosomal phosphorylation sites within the activation segments of both isoforms of the glycogen synthase kinase-3 (GeneDB accession no. Tb927.7.2420 and Tb10.61.3140) and a DYRK homologue (GeneDB accession no. Tb11.02.0640) (Nett et al., submitted for publication) strongly supports the view that known kinase-activating sites are conserved in T. brucei and indicates that several segments of known signal transduction pathways are conserved in this organism.
This study also provided an insight into the localization of tyrosine-phosphorylated proteins in both life cycle stages of T. brucei. Proteins carrying this posttranslational modification were found to be concentrated at the cytoskeleton, specifically with the axoneme and the basal bodies of the flagellum, as well as the nucleolar compartment of the parasite, as determined by immunofluorescence microscopy. This is in stark contrast to the localization pattern of tyrosine-phosphorylated proteins in mammalian cells, in which the signal for this posttranslational modification is concentrated at the plasma membrane in focal adhesion points that are known as locations for high tyrosine kinase activity (40). In these studies, it is difficult to correlate phosphotyrosine proteome data with localization data, since the former are based on the purification of phosphotyrosine-containing tryptic peptides, whereas the latter are based on antibody recognition in the context of folded and fixed proteins. Therefore, we cannot say what proportion of the phosphoproteome is associated with the cyctoskeletal and nucleolar compartments nor what subset of phosphoproteins might be specific for those locations. Nevertheless, the lack of conventional receptor tyrosine kinases and nonreceptor tyrosine kinases in T. brucei might be one aspect of the different staining patterns observed between trypanosomes and mammalian cells. The different locations of phosphotyrosine-containing proteins in the human system and the parasite might also directly reflect different functions of phosphotyrosine-based signaling in the organisms due to their substantially different requirements for survival.
Work by Das et al. (11) has identified a tyrosine-phosphorylated NOPP44/46 protein with a nucleolar localization in procyclic trypanosomes. This observation is consistent with our detection of a phosphotyrosine signal in the nucleolus of procyclic form cells by immunofluorescence. It remains unclear whether our microscopy studies also detected the NOPP44/46 protein, as it was not detected in our focused tyrosine phosphoproteomics screen of whole procyclic form cells. However, analysis of the NOPP44/46 amino acid sequence (GeneDB accession no. Tb927.8.760) reveals that, of the five tyrosine residues it contains, at least four of them are undetectable by MS. One is the C-terminal residue in the sequence RY (the tryptic product would be too small to detect), and three reside in tryptic peptides with masses of 6,947 Da (two sites) and 7,440 Da (one site) that are too large to provide meaningful MS-MS spectra. Only the N-terminal tyrosine residue (Y) in the sequence MEGFYGVEVSAGQKVK would be potentially detectable by our method. However, there is no guarantee that this is a phosphorylation site in NOPP44/46, and in any phosphoproteome analysis there is no guarantee that every occupied site will be detected. NOPP44/46 has been shown to bind nucleic acid (11), and RNA interference of the T. brucei-specific protein in the procyclic form affects large-subunit rRNA processing (19). This raises the interesting question of whether growth control and development of T. brucei are mediated by nucleolus-localized tyrosine-phosphorylated proteins, with ribosome synthesis as the obvious target of regulation. A more targeted phosphoprotomics study of T. brucei nucleoli could provide answers to the questions of how these nucleolus-localized tyrosine-phosphorylated proteins operate and if there is a connection to known signaling pathways.
The observation of tyrosine-phosphorylated proteins located on the basal body and along the axoneme of the flagellum extending to its distal tip is intriguing, as it suggests that signaling molecules could be associated with microtubules, which has been shown with mammalian cells (26). In fact, in mammalian cells, many kinases, such as MAPK, MEK1, MEK2, Raf1 (MEKK), CDK5, and CDC2, as well as many phosphatases, such as protein phosphatase 2A (PP2A), protein phosphatase 2B (PP2B), and protein phosphatase 1 (PP1), were detected in microtubule pellets, indicating that microtubule assembly and stability might be regulated by an interplay of these signaling molecules. The same study also revealed that the pool of microtubule-associated MAPK was constitutively active, which would be consistent with our observation that the phosphotyrosine signal along the flagellum and on the basal body was cell cycle independent.
Interestingly, a recent study of the green alga Chlamydomonas reinhardtii has shown that the tyrosine-phosphorylated active form of GSK3 was enriched in the flagellum (43). RNA interference of Chlamydomonas reinhardtii GSK3 resulted in cells that had no flagella, suggesting a role for GSK3 in assembly and maintenance of flagella, presumably through the regulation of intraflagellar transport. Our study showed that tyrosine-phosphorylated proteins are associated with the flagellum and the basal body, which is an organelle that provides a platform for recruiting proteins involved in intraflagellar transport (34). In addition, we identified TbGSK3 phosphorylated in its activation loop, suggesting that the kinase is active in the parasite. Both flagellum formation and basal body segregation are vital for T. brucei (4, 13), and our findings indicate that tyrosine-phosphorylated proteins might play a role in these essential processes.
I.R.E.N. was supported by a Wellcome Trust Prize Ph.D. studentship. M.A.J.F. is supported by a Wellcome Trust program grant (085622). L.D. is supported by an MRC program grant and the Dundee DSTT consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck and Co., Merck KGaA, and Pfizer).
Published ahead of print on 30 January 2009. ![]()
Supplemental material for this article may be found at http://ec.asm.org/. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»